Information from the President of URPL regarding the European Medicines Agency's PRAC Committee's review of data on the risk of suicidal thoughts during therapy with GLP-1 receptor agonists.
The EMA's safety committee, PRAC, is reviewing data on the risk of suicidal thoughts and thoughts of self-harm associated with the use of drugs known as GLP-1 receptor agonists (dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide), including Ozempic (semaglutide), Saxenda (liraglutide) and Wegova (semaglutide). These drugs are used to reduce weight and treat type 2 diabetes.
The review was initiated by Iceland's drug agency after reports of suicidal thoughts and self-harm in users of drugs containing liraglutide and semaglutide. To date, authorities have collected and are analyzing about 150 reports of poss...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
